Itaconix（18G0）株式概要Itaconix plcは、その子会社とともに、北米とヨーロッパでホームケアおよびパーソナルケア用途の植物由来ポリマーの開発に従事している。 詳細18G0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間19%増加すると予測されています リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間6.3%減少しました。 意味のある時価総額がありません ( €16M )すべてのリスクチェックを見る18G0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.0360.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-14m25m2016201920222025202620282031Revenue US$25.1mEarnings US$2.4mAdvancedSet Fair ValueView all narrativesItaconix plc 競合他社EcoRubSymbol: DB:7M8Market cap: €40.2mIBU-tec advanced materialsSymbol: XTRA:IBUMarket cap: €77.2mSIMONASymbol: DB:SIM0Market cap: €300.0mBio-GateSymbol: DB:BIG1Market cap: €7.2m価格と性能株価の高値、安値、推移の概要Itaconix過去の株価現在の株価UK£1.0352週高値UK£1.5252週安値UK£1.01ベータ1.061ヶ月の変化-1.90%3ヶ月変化-14.88%1年変化0%3年間の変化-49.14%5年間の変化-87.59%IPOからの変化-58.80%最新ニュースお知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025最新情報をもっと見るRecent updatesお知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025お知らせ • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€21.4m market cap, or US$23.7m).New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€23.5m market cap, or US$26.1m).お知らせ • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024お知らせ • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.お知らせ • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.お知らせ • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.お知らせ • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United KingdomReported Earnings • Apr 16Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (€41.3m market cap, or US$44.6m).お知らせ • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.お知らせ • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.Reported Earnings • Sep 17First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany.お知らせ • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023New Risk • Aug 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 28% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$708k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€30.5m market cap, or US$33.0m).New Risk • Jun 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€36.2m market cap, or US$39.0m).Reported Earnings • Jun 05Full year 2022 earnings released: US$0.50 loss per share (vs US$0.001 loss in FY 2021)Full year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.お知らせ • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdomお知らせ • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.お知らせ • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 15First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021)First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.お知らせ • Sep 14Itaconix plc Provides Earnings Guidance for the Full Year 2022Itaconix plc provided earnings guidance for the full year 2022. For the year, the company remains on course to deliver revenues ahead of current market expectations based on progress in commercial volumes and success in passing on increases in direct costs.お知らせ • Sep 07Itaconix plc to Report First Half, 2022 Results on Sep 14, 2022Itaconix plc announced that they will report first half, 2022 results on Sep 14, 2022Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 20Itaconix plc Appoints Laura Denner as Executive DirectorLaura Denner is appointed to the Board of Itaconix as an Executive Director effective July 20, 2022. Laura has assumed increasing finance, accounting, and operations responsibilities since joining Itaconix Corporation in 2013. She has served as the Company's Chief Financial Officer since 2018. Previously, she worked as Audit Manager for Feeley & Driscoll (now within BDO). Sheholds a Master of Science degree in accounting from Boston College and a Bachelor of Arts degree in accounting and international studies from Bryant University. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Interim Chair), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).お知らせ • Jul 05Itaconix plc Announces Directorate ChangeItaconix announced changes to the Board. Dr. James Barber has stepped down as Chair and Non-Executive Director of the Board with immediate effect. Dr. Barber served as a Non-Executive Director of Itaconix plc since 2016 and Chair since 2018. He also served as a Director of Itaconix Corporation from 2012 to 2016. Dr. Peter Nieuwenhuizen isappointed to the Board as a Non-Executive Director and Interim Chair with immediate effect. He is a Founding Partner of the European Circular Bioeconomy Fund ("ECBF"), a €300 million venture capitalfund dedicated to the circular bioeconomy. He serves as Chair of the Green Chemistry and Commerce Council, as Boardmember of PeelPioneers B.V. and In Ovo Holding B.V., and as an advisor to Solugen LLC and to Cosun (Coöperatie Koninklijke Cosun U.A.). Prior to co-founding ECBF, Peter was CTO & Corporate Director RD&I & Sustainability for AkzoNobel Specialty Chemicals (now Nouryon B.V.) and CTO of Enerkem Inc.He earned his Ph.D. in Chemistry from Leiden University. As a result, the Board now comprises Dr. Nieuwenhuizen (Non-Executive Interim Chairman) and John R. Shaw (Chief Executive Officer). The Company is actively working on further Board appointments, to include recruitment of an additional independent non executive director.Breakeven Date Change • Jun 10Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 46% is required to achieve expected profit on schedule.Reported Earnings • Jun 09Full year 2021 earnings released: US$0.001 loss per share (vs US$0.005 loss in FY 2020)Full year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Over the next year, revenue is forecast to grow 81%, compared to a 6.5% growth forecast for the industry in Germany.Board Change • May 31High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.お知らせ • May 27+ 1 more updateItaconix plc, Annual General Meeting, Jul 01, 2022Itaconix plc, Annual General Meeting, Jul 01, 2022, at 12:00 Coordinated Universal Time. Location: Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdomお知らせ • May 08Itaconix plc announced that it has received $0.06525 million in fundingOn May 6, 2022, Itaconix Plc closed the transaction. The transaction included participation from 2 investors.Board Change • Apr 27High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.お知らせ • Apr 19Itaconix plc Announces Board ChangesItaconix plc announced that Dr. Bryan Dobson will retire as an independent non-executive director, to be replaced by Charlean Gmunder, with immediate effect. Ms. Gmunder is chief operating officer of Blue Apron Holdings Inc.Board Change • Mar 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 10Itaconix plc Announces Supplied Product for the First Production Trial Using the Company's Plant-Based Superabsorbent, Velafresh® Sap80Itaconix announced that it has supplied product for the first production trial using the Company's plant-based superabsorbent, VELAFRESH® SAP80. VELAFRESH® SAP80 is being trialed by a leading supplier to companies that produce baby diapers, feminine hygiene products, adult diapers, and industrial absorption products. This follows the Company's production trials for VELAFRESH® SAP80 in 2021. If the prospective customer's trials are favourable, potential Itaconix revenues are expected to start in 2023. Increasing consumer interest in more sustainable hygiene products is generating new addressable markets for Itaconix's plant-based polymers. The worldwide market for superabsorbent polymers (SAPs) was estimated at $9.0 billion in 2020 and is supplied almost entirely by fossil-based polymers due to the higher cost or lower performance of current plant-based polymers. The Company believes VELAFRESH® SAP80 offers a superior level of performance, cost, and availability for brands and consumers that are seeking more sustainable hygiene products.お知らせ • Feb 03Itaconix plc Extends its Technology Platform into Potential Uses in Composite Materials and Files New Patent to Protect Innovative Intellectual PropertyItaconix plc announced that the Company is extending the Itaconix technology platform into potential uses in composite materials and has filed a new patent to protect innovative intellectual property for expected applications in this new area. The extension of the Itaconix technology platform is part of the Company's efforts to engage with potential customers to identify sizable unmet needs that Itaconix can address with plant-based solutions. Market and materials research led by Dr. Yvon Durant, Itaconix's CTO, has created a path to making certain composite materials that may allow a safer process to produce products that also have higher plant-based content. If granted, the patent will protect a new family of intellectual property for Itaconix. The review process for the filing is expected to take at least two years, and there is no guarantee that the patent will be granted. Product research based on this patent filing will now enter the next stage of commercial development. Key milestones for 2022 are to complete initial environmental and safety studies and to engage in commercial discussions with market collaborators.お知らせ • Jan 26Itaconix plc Provides Revenue Guidance for the Year Ended 31 December 2021Itaconix plc provided revenue guidance for the year ended 31 December 2021. The company expects to report results in line with market expectations with revenues of $2.6 million.お知らせ • Dec 22Itaconix plc Provides Update on Production ResumptionItaconix plc provide an update to the 4 November 2021 announcement regarding the temporary interruption to operations due to water damage. The Company was successful with interim measures to resume production in the middle of November, with permanent repairs scheduled to be completed in the coming weeks. Itaconix has met and expects to continue to meet all customer orders. The Company is working closely with one large customer on minor delivery delays that will not impact the customer's operating needs. Itaconix has filed a claim with the relevant insurers to cover the costs of both property damage and operational costs incurred.Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 09Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million.Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,091,115 Price\Range: £0.121 Discount Per Security: £0.032 Transaction Features: Subsequent Direct Listing株主還元18G0DE ChemicalsDE 市場7D-5.5%-0.3%3.2%1Y0%5.7%2.5%株主還元を見る業界別リターン: 18G0過去 1 年間で5.7 % の収益を上げたGerman Chemicals業界を下回りました。リターン対市場: 18G0は、過去 1 年間で2.5 % のリターンをもたらしたGermanマーケットと一致しました。価格変動Is 18G0's price volatile compared to industry and market?18G0 volatility18G0 Average Weekly Movement14.8%Chemicals Industry Average Movement6.0%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: 18G0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 18G0の 週次ボラティリティ は、過去 1 年間で9%から15%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト200528John Shawitaconix.comItaconix plc は子会社とともに、北米とヨーロッパでホームケアおよびパーソナルケア用途の植物由来ポリマーの開発に従事している。Itaconix DSP 2K、Itaconix TSI 122、Itaconix TSI 322、Itaconix ONZ 100、Itaconix ONZ 105、Itaconix ONZ 400、Itaconix ONZ 075、Itaconix SF 505などのクリーニング製品、ベラフレッシュZP20、ベラフレッシュZP30、ベラフレッシュZP75、ベラフレッシュZP95、ベラフレッシュNE 100などの衛生・美容製品を提供している。同社は以前はRevolymer plcとして知られていたが、2017年2月にItaconix plcに社名を変更した。Itaconix plcは2005年に設立され、ニューハンプシャー州ストラスハムに本社を置いている。もっと見るItaconix plc 基礎のまとめItaconix の収益と売上を時価総額と比較するとどうか。18G0 基礎統計学時価総額€16.40m収益（TTM）-€1.19m売上高(TTM)€9.05m1.8xP/Sレシオ-13.8xPER（株価収益率18G0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計18G0 損益計算書（TTM）収益US$10.50m売上原価US$6.86m売上総利益US$3.64mその他の費用US$5.02m収益-US$1.38m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.10グロス・マージン34.69%純利益率-13.14%有利子負債／自己資本比率0%18G0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:27終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Itaconix plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alexander BrooksCanaccord Genuity
お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.
お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.
お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
お知らせ • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€21.4m market cap, or US$23.7m).
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€23.5m market cap, or US$26.1m).
お知らせ • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024
お知らせ • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.
お知らせ • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.
お知らせ • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.
お知らせ • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United Kingdom
Reported Earnings • Apr 16Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (€41.3m market cap, or US$44.6m).
お知らせ • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.
お知らせ • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.
Reported Earnings • Sep 17First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany.
お知らせ • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023
New Risk • Aug 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 28% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$708k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€30.5m market cap, or US$33.0m).
New Risk • Jun 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (€36.2m market cap, or US$39.0m).
Reported Earnings • Jun 05Full year 2022 earnings released: US$0.50 loss per share (vs US$0.001 loss in FY 2021)Full year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.
お知らせ • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdom
お知らせ • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.
お知らせ • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 15First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021)First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.
お知らせ • Sep 14Itaconix plc Provides Earnings Guidance for the Full Year 2022Itaconix plc provided earnings guidance for the full year 2022. For the year, the company remains on course to deliver revenues ahead of current market expectations based on progress in commercial volumes and success in passing on increases in direct costs.
お知らせ • Sep 07Itaconix plc to Report First Half, 2022 Results on Sep 14, 2022Itaconix plc announced that they will report first half, 2022 results on Sep 14, 2022
Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 20Itaconix plc Appoints Laura Denner as Executive DirectorLaura Denner is appointed to the Board of Itaconix as an Executive Director effective July 20, 2022. Laura has assumed increasing finance, accounting, and operations responsibilities since joining Itaconix Corporation in 2013. She has served as the Company's Chief Financial Officer since 2018. Previously, she worked as Audit Manager for Feeley & Driscoll (now within BDO). Sheholds a Master of Science degree in accounting from Boston College and a Bachelor of Arts degree in accounting and international studies from Bryant University. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Interim Chair), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).
お知らせ • Jul 05Itaconix plc Announces Directorate ChangeItaconix announced changes to the Board. Dr. James Barber has stepped down as Chair and Non-Executive Director of the Board with immediate effect. Dr. Barber served as a Non-Executive Director of Itaconix plc since 2016 and Chair since 2018. He also served as a Director of Itaconix Corporation from 2012 to 2016. Dr. Peter Nieuwenhuizen isappointed to the Board as a Non-Executive Director and Interim Chair with immediate effect. He is a Founding Partner of the European Circular Bioeconomy Fund ("ECBF"), a €300 million venture capitalfund dedicated to the circular bioeconomy. He serves as Chair of the Green Chemistry and Commerce Council, as Boardmember of PeelPioneers B.V. and In Ovo Holding B.V., and as an advisor to Solugen LLC and to Cosun (Coöperatie Koninklijke Cosun U.A.). Prior to co-founding ECBF, Peter was CTO & Corporate Director RD&I & Sustainability for AkzoNobel Specialty Chemicals (now Nouryon B.V.) and CTO of Enerkem Inc.He earned his Ph.D. in Chemistry from Leiden University. As a result, the Board now comprises Dr. Nieuwenhuizen (Non-Executive Interim Chairman) and John R. Shaw (Chief Executive Officer). The Company is actively working on further Board appointments, to include recruitment of an additional independent non executive director.
Breakeven Date Change • Jun 10Forecast to breakeven in 2024The analyst covering Itaconix expects the company to break even for the first time. New forecast suggests the company will make a profit of US$199.5k in 2024. Average annual earnings growth of 46% is required to achieve expected profit on schedule.
Reported Earnings • Jun 09Full year 2021 earnings released: US$0.001 loss per share (vs US$0.005 loss in FY 2020)Full year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Over the next year, revenue is forecast to grow 81%, compared to a 6.5% growth forecast for the industry in Germany.
Board Change • May 31High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.
お知らせ • May 27+ 1 more updateItaconix plc, Annual General Meeting, Jul 01, 2022Itaconix plc, Annual General Meeting, Jul 01, 2022, at 12:00 Coordinated Universal Time. Location: Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom
お知らせ • May 08Itaconix plc announced that it has received $0.06525 million in fundingOn May 6, 2022, Itaconix Plc closed the transaction. The transaction included participation from 2 investors.
Board Change • Apr 27High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.
お知らせ • Apr 19Itaconix plc Announces Board ChangesItaconix plc announced that Dr. Bryan Dobson will retire as an independent non-executive director, to be replaced by Charlean Gmunder, with immediate effect. Ms. Gmunder is chief operating officer of Blue Apron Holdings Inc.
Board Change • Mar 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 10Itaconix plc Announces Supplied Product for the First Production Trial Using the Company's Plant-Based Superabsorbent, Velafresh® Sap80Itaconix announced that it has supplied product for the first production trial using the Company's plant-based superabsorbent, VELAFRESH® SAP80. VELAFRESH® SAP80 is being trialed by a leading supplier to companies that produce baby diapers, feminine hygiene products, adult diapers, and industrial absorption products. This follows the Company's production trials for VELAFRESH® SAP80 in 2021. If the prospective customer's trials are favourable, potential Itaconix revenues are expected to start in 2023. Increasing consumer interest in more sustainable hygiene products is generating new addressable markets for Itaconix's plant-based polymers. The worldwide market for superabsorbent polymers (SAPs) was estimated at $9.0 billion in 2020 and is supplied almost entirely by fossil-based polymers due to the higher cost or lower performance of current plant-based polymers. The Company believes VELAFRESH® SAP80 offers a superior level of performance, cost, and availability for brands and consumers that are seeking more sustainable hygiene products.
お知らせ • Feb 03Itaconix plc Extends its Technology Platform into Potential Uses in Composite Materials and Files New Patent to Protect Innovative Intellectual PropertyItaconix plc announced that the Company is extending the Itaconix technology platform into potential uses in composite materials and has filed a new patent to protect innovative intellectual property for expected applications in this new area. The extension of the Itaconix technology platform is part of the Company's efforts to engage with potential customers to identify sizable unmet needs that Itaconix can address with plant-based solutions. Market and materials research led by Dr. Yvon Durant, Itaconix's CTO, has created a path to making certain composite materials that may allow a safer process to produce products that also have higher plant-based content. If granted, the patent will protect a new family of intellectual property for Itaconix. The review process for the filing is expected to take at least two years, and there is no guarantee that the patent will be granted. Product research based on this patent filing will now enter the next stage of commercial development. Key milestones for 2022 are to complete initial environmental and safety studies and to engage in commercial discussions with market collaborators.
お知らせ • Jan 26Itaconix plc Provides Revenue Guidance for the Year Ended 31 December 2021Itaconix plc provided revenue guidance for the year ended 31 December 2021. The company expects to report results in line with market expectations with revenues of $2.6 million.
お知らせ • Dec 22Itaconix plc Provides Update on Production ResumptionItaconix plc provide an update to the 4 November 2021 announcement regarding the temporary interruption to operations due to water damage. The Company was successful with interim measures to resume production in the middle of November, with permanent repairs scheduled to be completed in the coming weeks. Itaconix has met and expects to continue to meet all customer orders. The Company is working closely with one large customer on minor delivery delays that will not impact the customer's operating needs. Itaconix has filed a claim with the relevant insurers to cover the costs of both property damage and operational costs incurred.
Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 09Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million.Itaconix plc has completed a Follow-on Equity Offering in the amount of £1.100025 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,091,115 Price\Range: £0.121 Discount Per Security: £0.032 Transaction Features: Subsequent Direct Listing
